The Food and Drug Administration’s quick approval of new mobile medical apps designed for the Apple Watch is raising eyebrows among FDA observers who say the tech behemoth got preferential treatment.
Last week, the FDA granted—in two separate letters dated September 11—two different “de novo decisions” in Apple’s favor, according to Bradley Merrill Thompson, an attorney at Washington-based law firm Epstein Becker Green who counsels medical device companies on regulatory issues.
